Geode Capital Management LLC Grows Stake in Hologic, Inc. (NASDAQ:HOLX)

Geode Capital Management LLC lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,732,131 shares of the medical equipment provider’s stock after purchasing an additional 144,838 shares during the quarter. Geode Capital Management LLC owned about 2.54% of Hologic worth $412,159,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. General Partner Inc. acquired a new position in Hologic during the fourth quarter valued at $26,000. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. Finally, Smithfield Trust Co lifted its holdings in Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.3 %

Shares of Hologic stock opened at $60.86 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.66 billion, a price-to-earnings ratio of 19.20, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52-week low of $59.06 and a 52-week high of $84.67. The company’s 50-day simple moving average is $64.30 and its 200-day simple moving average is $72.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HOLX. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Raymond James reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Finally, Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.